US20200190471A1 - In vitro immune synapse system and method of in vitro evaluating immune response using the same - Google Patents

In vitro immune synapse system and method of in vitro evaluating immune response using the same Download PDF

Info

Publication number
US20200190471A1
US20200190471A1 US16/219,006 US201816219006A US2020190471A1 US 20200190471 A1 US20200190471 A1 US 20200190471A1 US 201816219006 A US201816219006 A US 201816219006A US 2020190471 A1 US2020190471 A1 US 2020190471A1
Authority
US
United States
Prior art keywords
cell
vitro
cells
antigen
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/219,006
Inventor
Hso-Chi Chaung
Wen-Bin Chung
Ann Ying-An Chen
Mei-Li WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Pingtung University of Science and Technology
Original Assignee
National Pingtung University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Pingtung University of Science and Technology filed Critical National Pingtung University of Science and Technology
Priority to US16/219,006 priority Critical patent/US20200190471A1/en
Assigned to NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY reassignment NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHAUNG, HSO-CHI, CHEN, ANN YING-AN, CHUNG, WEN-BIN, WU, MEI-LI
Publication of US20200190471A1 publication Critical patent/US20200190471A1/en
Priority to US17/021,158 priority patent/US11834647B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1164—NK cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Definitions

  • the present invention relates to an in vitro simulating immune system and a method of evaluating immune response using the same. More particularly, the present invention relates to an in vitro immune synapse system using various immune cells for in vitro evaluating immune response by various immune cells and a method of in vitro evaluating immune response using the same.
  • the vaccine is a top strategy for controlling all diseases, so it is a main critical issue on global public health to develop safe, effective, and timely available vaccines against pathogens.
  • animal experimentations are still necessarily used in testing, screening and finding out antigens and adjuvants with better immune effects during the development of animal vaccines.
  • it costs a lot for animal experimentation required for developing vaccines and immune adjuvants.
  • use of animal experimentation in developing vaccines is also limited by the species specificity of animal immune systems, and an experimental result from one species of animals against one pathogen does not necessarily mirror results of other species of animals against other pathogens.
  • mice are of small sizes and the number of immune cells taken from each mouse is very limited.
  • the sufficient immune cells required for one test must be collected from different individual mice.
  • the co-culture of immune cells from different individuals and species can easily lead to various immune rejections. Therefore, with regard to the immune cells taken from different individuals, evaluation can only be performed by the same type of immune cells, and thus T cell epitope-based evaluation cannot be conducted by the same type of immune cells.
  • one aspect of the present invention provides an in vitro immune synapse system, which includes antigen-presenting cells derived from a same individual pig and at least one cell type of several specific T cell subtypes isolated from peripheral blood mononuclear cells (PBMCs).
  • PBMCs peripheral blood mononuclear cells
  • Another aspect of the present invention provides a method of in vitro evaluating immune response, which includes co-culturing a test sample in the aforementioned in vitro immune synapse system for a given period, and then detecting the immune synapse system for any immunization-related changes so as to determine whether the test sample is immunogenic, immunostimulatory or not, thereby replacing animal experimentation.
  • an in vitro immune synapse system which includes antigen-presenting cells and at least one cell type of regulatory T cells, killer cells, and helper T cells.
  • the aforementioned antigen-presenting cells, regulatory T cells, killer cells, and helper T cells are primary cells derived from a same individual, and the number of the antigen-presenting cells can be, for example, larger than the total number of the regulatory T cells, the killer cells and the helper T cells.
  • the aforementioned same individual is a specific pathogen free (SPF) pig.
  • SPF pathogen free
  • the aforementioned antigen-presenting cells can be, for example, alveolar macrophages.
  • the aforementioned in vitro immune synapse system includes, for example, at least one cell type of the antigen-presenting cells, regulatory T cells, killer cells, and helper T cells, as well as control cells, and the antigen-presenting cells, regulatory T cells, killer cells, helper T cells and control cells are primary cells derived from a same individual.
  • the test sample is co-cultured in the aforementioned immune synapse system for 24 to 48 hours.
  • the aforementioned immune synapse system is detected for any immunization-related changes, where the immunization-related changes can be, for example, TLR gene expression level and/or concentration cell cytokine.
  • the test sample is determined to be immunogenic or immunostimulatory.
  • the aforementioned test sample can be, for example, antigens or adjuvants.
  • control cells can be, for example, mononuclear cells.
  • an in vitro immune synapse system including antigen-presenting cells derived from a same individual pig and several specific T-cell subtypes isolated from peripheral blood mononuclear cells is employed to evaluate the T-cell antigen epitope of the test sample.
  • the aforementioned in vitro immune synapse system does have consistent results with those of animal experimentation. Therefore, when developing new antigens or new adjuvants in the future, the aforementioned in vitro immune synapse system is expected to replace animal experimentation.
  • FIGS. 1A to 1D depict transmission electron microscopy (TEM) images ( FIGS. 1A to 1C ) and scanning election microscopy (SEM) images ( FIG. 1D ) of a porcine alveolar macrophage matching to a regulatory T cell ( FIGS. 1A and 1B ) or matching to a helper T cell ( FIGS. 1C and 1D ) according to an embodiment of the present invention;
  • TEM transmission electron microscopy
  • SEM scanning election microscopy
  • FIGS. 2A to 2C depict bar diagrams of mRNA relative expression levels of toll-like receptors (TLRs) 3 ( FIG. 2A ), TLR7 ( FIG. 2B ), and TLR8 ( FIG. 2C ) upon the in vitro co-culturation of the antigen-presenting cell together with the regulatory T cell, the killer cell, the helper T cell and the control cell, respectively, for an individual pig that is immunized by different Porcine Reproductive and Respiratory Syndrome (PRRS) antigens according to an embodiment of the present invention;
  • PRRS Porcine Reproductive and Respiratory Syndrome
  • FIGS. 3A to 3B depict bar diagrams of the IL-2 ( FIG. 3A ) level and IL-10 ( FIG. 3B ) level upon the co-culturation of the antigen-presenting cell with the regulatory T cell, the killer cell, the helper T cell and the control cell, respectively, for an individual pig that is immunized by different PRRS antigens according to an embodiment of the present invention;
  • FIG. 4 depicts a bar diagram of a TLR mRNA relative expression level of the immune adjuvant that is screened by an in vitro immune synapse system (including porcine helper T cells and alveolar macrophages) according to an embodiment of the present invention
  • FIG. 5 depicts a bar diagram of the IL-2 level of the immune adjuvant that is screened by an in vitro immune synapse system according to an embodiment of the present invention.
  • the present invention provides an immunological synapse (IS) system and the method of in vitro evaluating immune response using the same, the system being an immunological synapse system including antigen-presenting cells (APCs) derived from a same individual pig and several specific T-cell subtypes isolated from peripheral blood mononuclear cells (PBMCs), which is used to evaluate the T-cell epitope of a test sample.
  • APCs antigen-presenting cells
  • PBMCs peripheral blood mononuclear cells
  • the immunological synapse (IS) mentioned here in the present invention refers to the one formed by APCs and the T-cell subtypes of PBMCs in vitro.
  • the aforementioned immunological synapse (IS) which is a hypothesis proposed by researchers in recent years, is defined as a stable and collaborative interaction between two or more types of cells in the immune system, and causes consequent responses of at least one cell type of the cells.
  • This IS system fully covers essential factors required for the in vivo immune responses of an animal, including integration information between APCs and different T-cell subtypes (such as an antigen identification system), soluble factors with guiding functions (such as cell cytokines), and the intermolecular interaction for forming specific immune responses (such as the intercellular receptor-ligand binding system).
  • integration information between APCs and different T-cell subtypes such as an antigen identification system
  • soluble factors with guiding functions such as cell cytokines
  • the intermolecular interaction for forming specific immune responses such as the intercellular receptor-ligand binding system.
  • APC plays a critical role in initiating and maintaining the immune response.
  • APC identifies a pathogen recognition molecular pattern (PAMP) by the pathogen recognition receptor (PRR) of an immune system, and initiates a specific immune path through signaling transduction.
  • PAMP pathogen recognition molecular pattern
  • PRR pathogen recognition receptor
  • APC is activated by antigens or adjuvants, profiles of various cytokines or proinflammatory cytokines are generated through identification of PRR, so as to influence the differentiation and proliferation of various T-cell subtypes, all of which can determine that the immune response trends to what kind of the immune cell or what pattern of proinflammatory cell response.
  • the toll-like receptor (TLR) is the major family of PRRs.
  • TLR toll-like receptor
  • APC and TLR have provided a great deal of new information about the development of immune mechanisms and vaccines/adjuvants both related to a TLR agonist.
  • the TLR agonists and the cell cytokines can change the micro-environment in which the APCs contact the T cells, thereby affecting the stability during the IS formation between the two cells.
  • the deeper we discover the effect of the TLR agonists and cell cytokines on the IS formation between a specific antigen or infected APCs and the T cells the more we can effectively apply the TLR agonists and cell cytokines on the immune adjuvant of animal vaccines.
  • TLR agonists There are kinds of TLR agonists now being attempted as the immune regulator or an active ingradient in the immune adjuvant, but a specific cell cytokine is required to involve in the micro-environment in which the APC contacts the T cells, so as to form a stable IS.
  • a specific cell cytokine is required to involve in the micro-environment in which the APC contacts the T cells, so as to form a stable IS.
  • the research on how the interaction between TLR agonist and cell cytokine affects the IS formation is rare.
  • an in vitro immune synapse system of the present invention can include antigen-presenting cells and several specific T-cell subtypes isolated from PBMCs, the embodiment of which can include but be not limited to at least one cell type of regulatory T (Treg) cells, natural killer (NK) cells, and T helper (Th) cells.
  • the in vitro immune synapse system can also include an antigen-presenting cells; at least one cell type of a regulatory T cell, a killer cell and a helper T cell; and a control cell.
  • the antigen-presenting cell, the regulatory T cell, the killer cell, the helper T cell and the control cell are primary cells derived from a same individual, thereby overcoming the immune rejection.
  • the aforementioned same individual can be, for example, a specific pathogen free (SPF) pig of any known breeds.
  • Primary cells taken from the SPF pig can exclude interference of other antigens or antibodies. If the cells were not taken from the SPF pig, the test result of the antigen-presenting cells and the several specific T-cell subtypes isolated from peripheral blood mononuclear cells might be disturbed or even not able to obtain a result consistent with the animal experimentation.
  • the antigen-presenting cells referred in the present invention are not limited to their origin from body parts, depending on test samples.
  • the antigen-presenting cells can be alveolar macrophages (or referred to as alveolar cells); Langerhan's cells of skin; interdigitating cells (IDCs) of thymus; dendritic cells (DCs), activated B cells, macrophages and the like in the spleen and lymph nodes.
  • alveolar macrophages or referred to as alveolar cells
  • IDCs dendritic cells
  • activated B cells macrophages and the like in the spleen and lymph nodes.
  • the regulatory T cells referred in the present invention have preferably at least CD4 + /CD25 + cell marker.
  • the killer cells have preferably at least CD4 ⁇ /CD25 + cell marker.
  • the helper T cells have preferably at least CD4 + /CD25 ⁇ cell marker.
  • the control cells have preferably at least CD4 ⁇ /CD25 ⁇ cell marker, and in an example, they can be mononuclear cells.
  • the number of antigen-presenting cells is preferably larger than the total number of regulatory T cells, killer cells and helper T cells.
  • the number of antigen-presenting cells can be 2 to 10 times of total number of regulatory T cells, killer cells and helper T cells.
  • the number of antigen-presenting cells can also be larger than total number of regulatory T cells, killer cells, helper T cells and control cells.
  • the number of antigen-presenting cells can be 2 to 10 times of the total number of regulatory T cells, killer cells, helper T cells and control cells.
  • the aforementioned in vitro immune synapse system can be applied to the method of in vitro evaluating immune response.
  • the aforementioned in vitro immune synapse system is provided.
  • test sample is co-cultured in the aforementioned immune synapse system for a given period.
  • the test sample referred to in the present invention can be, for example, antigens or adjuvant, wherein types of the antigens and adjuvant should be known to one of ordinary skills in the art of the present invention rather than being recited herein.
  • the co-culturation referred in the present invention can include matching the antigen-presenting cells to any of several specific T-cell subtypes isolated from PBMCs, for example, matching the antigen-presenting cells to the regulatory T cells, the antigen-presenting cells with the helper T cells, and the antigen-presenting cells with the killer cells.
  • the aforementioned co-culturation can be implemented in a cell culture medium suitable for antigen-presenting cells and peripheral blood mononuclear cells.
  • the kinds of the cell culture medium is not limited but can be commercial products such as RPMI 1640 medium with 10% of pig serum or not.
  • a given period of the aforementioned co-culturation can be, for example, 6 to 24 hours, or 12 to 24 hours, or preferably 18 to 24 hours, and more preferably 24 hours.
  • the immunization-related changes are to be evaluated after co-culturation of the aforementioned matched cells.
  • the detection items for immunization-related changes are not limited, which can be, for example, a toll-like receptor (TLR) gene expression level, cytokine concentration and so on in an embodiment.
  • TLR toll-like receptor
  • the TLR gene expression level recited in the present invention can include but be not limited to the TLR3 gene expression level, TLR7 gene expression level and/or TLR8 gene expression level.
  • the cell cytokine concentration referred in the present invention can be, for example, the interleukin (IL) concentration, including but being not limited to IL-2 concentration and/or IL-10 concentration.
  • IL interleukin
  • the aforementioned test sample is immunogenic or immunostimulatory.
  • the significant difference described in the present invention refers to the statistically significant difference, typically P ⁇ 0.05.
  • PRRSV porcine reproductive and respiratory syndrome virus
  • the PRRSV is a major cause leading to serious respiratory symptoms of pigs in Taiwan. Once affected by PRRSV, a pig will be subjected to a high death rate, thereby extremely lowering the pig farm productivity.
  • PRRSV mainly affects pig APCs, especially immune functions between APCs affected by viruses and regulatory T cell (Treg) cells, changes immune cell activity, induces the differentiation and hyperplasia of different T-cell subtypes, reduces the antivirus immune response of the host, and thus makes the PRRSV avoid the host immune function.
  • the high pathogenic (HP) PRRSV has further caused serious porcine respiratory symptoms and great economic losses to the pig farming industry.
  • the respiratory mucosa immune system it is the most important topic regarding to enhancing the mucosa immune vaccine development that the antigen-presenting cell (APC) immune activity of the respiratory mucosa immune system is activated.
  • the respiratory mucosa immune system has alveolar macrophages as a primary first defense line of cells which are related to the interaction between a TLR agonist/cell cytokine and different T-cell antigen epitopes, but mechanisms used for their application in the animal mucosa immune IS formation and regulation are still outstanding.
  • the in vitro immune synapse system of the present invention does have results consistent with those of animal experimentation. Therefore, when developing new antigens or new adjuvant in future, the aforementioned in vitro immune synapse system is expected to replace animal experimentation.
  • PBMCs Peripheral Blood Mononuclear Cells
  • porcine PBMCs were isolated from a 4-week-old porcine PBMCs.
  • SPF pig (of a breed multiplied between Landrace and Yorkshire) by known methods. It should be mentioned that the age and strains of the aforementioned SPF pig were merely illustrative while not limited to the aforementioned, and pigs of other ages and breeds could also be used.
  • HBSS Hank's balanced salt solution
  • the PBMC layer was collected, then rinsed for 3 times by HBSS, adjusted its cell concentration by a RPMI-1640 cell culture medium containing 10% of pig serum (abbreviation as PS-RPMI), and then placed and cultured in an incubator under 37° C. for later use.
  • PS-RPMI RPMI-1640 cell culture medium containing 10% of pig serum
  • porcine PBMCs were collected the cell density of the cell solution were adjusted well, followed by adding the anti-porcine CD4 antibody and anti-porcine CD25 antibody into the cell solution, reacting the cell solution with the secondary antibodies, the cell solution was centrifuged at a 1000 ⁇ g for 5 minutes. Removing the supernatant, phosphate buffered solution (PBS) was added to resuspend the cell pellet, and Coulter Epics Altra Flow Cytometry (Beckman Coulter, Calif., USA) was used to analyze cell surface marks and sort cells.
  • PBS phosphate buffered solution
  • the target cells After the collection of the target cells, they were centrifuged to remove the supernatant, rinsed cells for 3 times by PBS, and added with PS-RPMI culture solution so as to resuspend the cells, and then placed and cultured them in an cell incubator under 37° C.
  • the cell solution was added with the anti-porcine CD4 and anti-porcine CD25 antibodies, and sorting quadrants were set by computer, in order to obtain the cell markers CD4 + /CD25 ⁇ (i.e., Th cell), CD4 ⁇ /CD25 + (i.e., NK cell), CD4 + /CD25 + (i.e., Treg cell), and CD4 ⁇ /CD25 ⁇ (i.e., control cell).
  • CD4 + /CD25 ⁇ i.e., Th cell
  • CD4 ⁇ /CD25 + i.e., NK cell
  • CD4 + /CD25 + i.e., Treg cell
  • the aforementioned cells were centrifuged to remove the supernatant, and then rinsed for 3 times by PBS, and added into the PS-RPMI medium to resuspend the cells, placed them into a cell incubator under 37° C. for culturation.
  • a SPF pig was anesthetized and immediately its lungs were excised. 200 mL of PBS was injected into the lungs through an endotracheal tube for rinsing and gently rubbing the lungs, and then the flushing fluid was collected. The flushing fluid was collected by a 50 mL plastic centrifuge tube, and centrifuged under 4° C. at 200 ⁇ g for 10 minutes, thereby collecting the cells deposited at the bottom, resuspend the cells in the PS-RPMI cell culture medium, and adjusting the cell concentration for subsequent use as antigen-presenting cells.
  • alveolar macrophages were respectively cultured in a 24-well cell culture plate with the RPMI-1640 culture medium, in which each well had 0.5 mL of antigen-presenting cell suspension (1 ⁇ 10 7 cells/mL). After cultured in an incubator containing 5% CO 2 under 37° C. for 24 hours, the cells were added with different sorted T-cell subtypes (i.e. Treg cells, Th cells, NK cells and control cells), respectively.
  • T-cell subtypes i.e. Treg cells, Th cells, NK cells and control cells
  • Each T-cell subtype was adjusted to 1 ⁇ 10 6 cells/mL, and 0.5 mL/well of cells for co-culture was added with antigen protein (2 ⁇ g/10 ⁇ L/well), and then added with the RPMI-1640 culture medium to a total volume of 1 mL for co-culture for 24 hours.
  • two repeats were used to identify the influence of different culture durations and antigen concentrations on the IS formation.
  • the cells were then reacted with 4-fold volume of 2% paraformaldehyde under 4 pa for 20 minutes of incubation, then added with equal volume of ammonium chloride under the room temperature for 20 minutes of incubation, followed by centrifuged at 500 ⁇ g for 10 minutes.
  • the cell layer was collected, added with fixed buffer solution, placed on ice for 10 minutes of incubation, and then analyzed for IS formation by the election microscopy.
  • the immunological synapse was a stable junction formed by antigen-presenting cells and target T cells, and also played a key role in the activation of the immune system.
  • the interaction between macrophages and T cells and the synapse structure formed by the two cells could be observed by transmission electron microscopy (TEM) and scanning election microscopy (SEM).
  • FIGS. 1A to 1D which were depicted TEM images ( FIGS. 1A to 1C ) and SEM image ( FIG. 1D ) of a porcine alveolar macrophage 101 matching to a regulatory T cell 103 ( FIGS. 1A and 1B ) or matching to a helper T cell 105 ( FIGS. 1C and 1D ) according to an embodiment of the present invention.
  • the regulatory T cell 103 would extend pseudopodia toward the alveolar macrophage 101 (as shown in FIG. 1A ).
  • the alveolar macrophage 101 and the regulatory T cell 103 showed centriole proximity (as shown in FIG. 1B ).
  • the Golgi complex of the alveolar macrophage 101 enlarged, the interface between the two cells was flatten (as shown in FIG. 1C ) and formed to the immunological synapse (as shown in FIG. 1D ), proving that the two cells were able to form the immune synapse system in vitro.
  • the “antigen 1” did not contain specific T-cell antigen epitope additionally, and the “antigen 2” contained specially T-cell antigen epitope additionally that was designed by inventors, wherein the T-cell antigen epitope of PRRSV as “antigen 2” had a sequence designed by the inventors.
  • PRRSV-1 and PRRSV-2 were merely illustrative examples for verifying the immune synapse system, and other known sequences could also be used without repeatedly described herein.
  • the aforementioned SPF pigs were sacrificed at 8 weeks old, and the alveolar macrophages and PBMCs were isolated respectively, in which the alveolar macrophages were used as the antigen-presenting cell (APC) which was then co-cultured with specific T-cell subtypes (i.e., Th cell, NK cell, Treg cell and control cell) sorted from the blood PBMCs by a flow cytometry, for providing evaluation on its function influenced by the animal immunization.
  • T-cell subtypes i.e., Th cell, NK cell, Treg cell and control cell
  • the TLR gene expression level of the aforementioned specific T-cell subtypes upon immunostimulation was measured by the following or conventional methods. Firstly, total RNA of the aforementioned specific T-cell subtypes was extracted by Trizol® reagent and Direct-Zol® column. After quantification by a spectrophotometer, a commercial kit [such as PrimeScriptTM RT reagent kit (Takara)] was used for synthesizing cDNA according to operation steps of the kit.
  • a commercial kit such as PrimeScriptTM RT reagent kit (Takara)
  • RNA was added into 2 ⁇ L of 5 ⁇ PCR buffer solution, 0.5 ⁇ L of PrimeScriptTM RT enzyme mix I, 0.5 ⁇ L of oligo-dT primer (50 ⁇ M), 0.5 ⁇ L of random primer (100 ⁇ M).
  • the volume of each reaction was added to 10 ⁇ L by double distilled (dd) H 2 O, and it was then treated under 42° C. for 30 minutes.
  • the expression level of TLR gene could be determined by the following primers and real time PCR.
  • the upstream primer of TLR3 gene was a sequence listed as SEQ ID NO: 1, while the downstream primer of TLR3 gene was a sequence listed as SEQ ID NO: 2.
  • the upstream primer of TLR7 gene was a sequence listed as SEQ ID NO: 3, while TLR7 gene downstream primer was a sequence listed as SEQ ID NO: 4.
  • the upstream primer of TLR8 gene was a sequence listed as SEQ ID NO: 5, while the downstream primer of TLR8 gene was a sequence listed as SEQ ID NO: 6.
  • FIGS. 2A to 2C which were bar diagrams of mRNA relative expression levels of toll-like receptors (TLRs) 3 ( FIG. 2A ), TLR 7 ( FIG. 2B ), and TLR 8 ( FIG. 2C ) upon the in vitro co-culturation of an antigen-presenting cell with a regulatory T cell, a killer cell, a helper T cell and a control cell, respectively, for an individual pig immunized by various PRRS antigens according to an embodiment of the present invention.
  • mRNA relative expression levels of TLR 3, TLR 7, and TLR 8 in FIGS. 2A to 2C were represented by ⁇ Ct in the geometric mean (2 ⁇ Ct .
  • the statistical significance between two groups (P ⁇ 0.05) was represented by their bars labeled by different letters of FIGS. 2A to 2C .
  • a commercial kit of porcine IL-2 and IL-10 was used for quantifying the IL-2 and IL-10 levels in the porcine cell supernatant.
  • the standard liquid provided by the kit was diluted for later use, and a flow was described briefly below. Firstly, 100 ⁇ L of sample or diluted standard liquid was added into a 96-well plate and incubated for 1 hour. Next, 200 ⁇ L of biotinylated antibody reagent was added into the 96-well plate and incubated for another hour.
  • the absorbance could be read by a commercial continuous spectrophotometer at a wavelength of 450/540 nm, and a standard curve was established by serially-diluted standard solution of various concentrations versus respective absorbances. Then, the cell cytokine concentration of each sample was calculated according to the regression equation of the standard curve, and a commercially statistical software (such as a SAS statistical program) was used to calculate significant difference between the means of all groups, as shown by the results of FIGS. 3A to 3B .
  • a commercially statistical software such as a SAS statistical program
  • FIGS. 3A to 3B depicted bar diagrams of the IL-2 ( FIG. 3A ) level and IL-10 ( FIG. 3B ) level upon the co-culturation of an antigen-presenting cell with a regulatory T cell, a killer cell, a helper T cell and a control cell, respectively, for an individual pig that was immunized by PRRS antigens according to an embodiment of the present invention.
  • the statistical significance between two groups was represented by their bars labeled by different letters of FIGS. 3A to 3B .
  • the IL-2 (having immunoenhancement) level could be effectively increased while the IL-10 (having immunosuppression) level was reduced.
  • the IL-10 level was inhibited more significantly, and the differences between these values had statistical significances.
  • alveolar macrophages and sorted T-cell subtypes were isolated from six 4-week-old specific pathogen free (SPF) pigs and co-cultured in a 24-well plate in order to establish an in vitro immune synapse system.
  • SPF pathogen free
  • the aforementioned in vitro immune synapse system was added with the antigen protein (the treatment group, 2 ⁇ g of PRRSV-1 or PRRSV-2) or without the antigen protein (the control group), and then the system was co-cultured in a CO 2 incubator under 37° C. for 24 hours. After the culturation, the 24-well plate was centrifuged at 300 ⁇ g for 15 minutes, and supernatants were respectively collected for detecting cell cytokines. Meanwhile, a Trizol® reagent (ThermoFisher Scientific) was used to dissolve the cell pellet, and the TLR gene expression was detected in the same method as Example 2, as shown by the result of FIG. 4 .
  • FIG. 4 which showed a bar diagram of a TLR mRNA relative expression level when the immune adjuvant was screened by an in vitro immune synapse system (including porcine helper T cells and alveolar macrophages) according to an embodiment of the present invention.
  • the statistical significance between two groups (P ⁇ 0.05) was represented by their bars labeled by different letters of FIG. 4 .
  • the PRRS antigen i.e., PRRSV-1 or PRRSV-2
  • the PRRS antigen did significantly improve the gene expression levels of TLR 3, TLR 7, and TLR 8 of the immunological synapse, and the differences between these values had statistical significances.
  • Example 2 After the in vitro immune synapse system (NK/APC or Treg/APC) of Example 1 was co-cultured with an immune adjuvant or not (control group), the IL-2 level was detected by the same method as Example 2.
  • the aforementioned immune adjuvant was poly IC (Sigma-Aldrich) and IL-18 (Sigma-Aldrich Co.). 2 ⁇ L of Poly IC (1 mg/mL) (Sigma-Aldrich Co.) was added into the cell sap per well (2 ⁇ g/well), or 100 ⁇ L IL-18 (1 ng/mL) (Sigma-Aldrich) was added into the cell sap per well (0.1 ng/well).
  • the detection methods for poly IC and IL-18 are referenced from J. Immunol. 162 (10):6114-6121 (May 15, 1999) and J. Immunol. 176:1348-1354 (2006), which are both incorporated by reference into the present invention.
  • FIG. 5 depicted a bar diagram of the IL-2 level ( ⁇ g/mL) of the immune adjuvant that was screened by an in vitro immune synapse system according to an embodiment of the present invention.
  • the statistical significance between two groups (P ⁇ 0.05) was represented by their bars labeled by different letters of FIG. 5 .
  • the in vitro immune synapse system in which Treg cells matched to APC cells could form the immunological synapse.
  • the poly-IC could significantly improve the IL-2 level in the immunological synapse, and the differences between these values had statistical significances.
  • the present invention utilizes cells from a specific source for establishing the in vitro immune synapse system, specific analysis methods or specific evaluations as examples to illustrate the in vitro immune synapse system of the present invention and the method of in vitro evaluating immune response using the same, any one of ordinary skills in the art of the present invention can realize that the present invention is not limited thereto.
  • cells from other sources can also be used for establishing the in vitro immune synapse system of the present invention and other analyzing methods or other evaluations can also be carried out in the method of in vitro evaluating immune response using the same.
  • an in vitro immune synapse system of the present invention and the method of in vitro evaluating immune response using the same are advantageous in the in vitro immune synapse system containing antigen-presenting cells derived from a same individual pig and several specific T-cell subtypes isolated from peripheral blood mononuclear cells, so as to evaluate the T-cell antigen epitope of a test sample.
  • the aforementioned in vitro immune synapse system indeed has results consistent with those of animal experimentation. Therefore, when developing new antigens or new adjuvants in the future, the aforementioned in vitro immune synapse system is expected to replace animal experimentation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to an in vitro immune synapse system and a method of in vitro evaluating immune response using the same. The in vitro immune synapse system includes antigen-presenting cells (APCs) and at least one cell type of several specific T cell subtypes isolated from peripheral blood mononuclear cells (PBMCs), all of which is from a same individual of pigs. When a test sample is co-cultured in the in vitro immune synapse system for a given period, it can be determined that the test sample is immunogenic, immunostimulatory or not according to the immunization-related changes of these cells, thereby potentially replacing some kinds of animal experimentation.

Description

    BACKGROUND Field of Invention
  • The present invention relates to an in vitro simulating immune system and a method of evaluating immune response using the same. More particularly, the present invention relates to an in vitro immune synapse system using various immune cells for in vitro evaluating immune response by various immune cells and a method of in vitro evaluating immune response using the same.
    • Description of Related Art
  • The vaccine is a top strategy for controlling all diseases, so it is a main critical issue on global public health to develop safe, effective, and timely available vaccines against pathogens.
  • Currently, animal experimentations are still necessarily used in testing, screening and finding out antigens and adjuvants with better immune effects during the development of animal vaccines. However, it costs a lot for animal experimentation required for developing vaccines and immune adjuvants. Moreover, the use of animal experimentation in developing vaccines is also limited by the species specificity of animal immune systems, and an experimental result from one species of animals against one pathogen does not necessarily mirror results of other species of animals against other pathogens.
  • Currently, there are some in vitro cell evaluation platforms in the market, however, these cells on the aforementioned platforms are mostly sourced from mice or commercially available cell lines. As a result, the evaluation results of those platforms cannot replace those from animal experimentation.
  • To be specific, mice are of small sizes and the number of immune cells taken from each mouse is very limited. The sufficient immune cells required for one test must be collected from different individual mice. However, the co-culture of immune cells from different individuals and species can easily lead to various immune rejections. Therefore, with regard to the immune cells taken from different individuals, evaluation can only be performed by the same type of immune cells, and thus T cell epitope-based evaluation cannot be conducted by the same type of immune cells.
  • As for commercially available immune cell lines, although there are enough cells, such cell lines are not primary cells, their cellular physiological metabolism, immune responses and the like are distinctly different from those of normal cells. Therefore, the resultant immune responses are quite low in credibility.
  • Accordingly, it is necessary to develop a system for in vitro evaluating immune response so as to overcome various disadvantages of conventional in vitro cell experimentation, thereby replacing animal experimentation.
    • SUMMARY
  • Therefore, one aspect of the present invention provides an in vitro immune synapse system, which includes antigen-presenting cells derived from a same individual pig and at least one cell type of several specific T cell subtypes isolated from peripheral blood mononuclear cells (PBMCs).
  • Another aspect of the present invention provides a method of in vitro evaluating immune response, which includes co-culturing a test sample in the aforementioned in vitro immune synapse system for a given period, and then detecting the immune synapse system for any immunization-related changes so as to determine whether the test sample is immunogenic, immunostimulatory or not, thereby replacing animal experimentation.
  • According to the aforesaid aspects of the present invention, an in vitro immune synapse system is provided, which includes antigen-presenting cells and at least one cell type of regulatory T cells, killer cells, and helper T cells. The aforementioned antigen-presenting cells, regulatory T cells, killer cells, and helper T cells are primary cells derived from a same individual, and the number of the antigen-presenting cells can be, for example, larger than the total number of the regulatory T cells, the killer cells and the helper T cells.
  • According to an embodiment of the present invention, the aforementioned same individual is a specific pathogen free (SPF) pig.
  • According to an embodiment of the present invention, the aforementioned antigen-presenting cells can be, for example, alveolar macrophages.
  • According to another aspect of the present invention, a method of in vitro evaluating immune response is provided. In an embodiment, first of all, the aforementioned in vitro immune synapse system is provided, where the in vitro immune synapse system includes, for example, at least one cell type of the antigen-presenting cells, regulatory T cells, killer cells, and helper T cells, as well as control cells, and the antigen-presenting cells, regulatory T cells, killer cells, helper T cells and control cells are primary cells derived from a same individual. Next, the test sample is co-cultured in the aforementioned immune synapse system for 24 to 48 hours. Then, the aforementioned immune synapse system is detected for any immunization-related changes, where the immunization-related changes can be, for example, TLR gene expression level and/or concentration cell cytokine. When an immunization-related change on any one of the regulatory T cells, killer cells and helper T cells has significant difference from an immunization-related change on the control cells, the test sample is determined to be immunogenic or immunostimulatory.
  • According to an embodiment of the present invention, the aforementioned test sample can be, for example, antigens or adjuvants.
  • According to an embodiment of the present invention, the aforementioned control cells can be, for example, mononuclear cells.
  • With application of the in vitro immune synapse system of the present invention and the method of in vitro evaluating immune response using the same, an in vitro immune synapse system including antigen-presenting cells derived from a same individual pig and several specific T-cell subtypes isolated from peripheral blood mononuclear cells is employed to evaluate the T-cell antigen epitope of the test sample. Through the verification of animal experimentation, the aforementioned in vitro immune synapse system does have consistent results with those of animal experimentation. Therefore, when developing new antigens or new adjuvants in the future, the aforementioned in vitro immune synapse system is expected to replace animal experimentation.
  • It is to be understood that both the foregoing general description and the following detailed description are by examples, and are intended to provide further explanation of the invention as claimed.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • The invention can be more fully understood by reading the following detailed description of the embodiment, with reference made to the accompanying drawings as follows:
  • FIGS. 1A to 1D depict transmission electron microscopy (TEM) images (FIGS. 1A to 1C) and scanning election microscopy (SEM) images (FIG. 1D) of a porcine alveolar macrophage matching to a regulatory T cell (FIGS. 1A and 1B) or matching to a helper T cell (FIGS. 1C and 1D) according to an embodiment of the present invention;
  • FIGS. 2A to 2C depict bar diagrams of mRNA relative expression levels of toll-like receptors (TLRs) 3 (FIG. 2A), TLR7 (FIG. 2B), and TLR8 (FIG. 2C) upon the in vitro co-culturation of the antigen-presenting cell together with the regulatory T cell, the killer cell, the helper T cell and the control cell, respectively, for an individual pig that is immunized by different Porcine Reproductive and Respiratory Syndrome (PRRS) antigens according to an embodiment of the present invention;
  • FIGS. 3A to 3B depict bar diagrams of the IL-2 (FIG. 3A) level and IL-10 (FIG. 3B) level upon the co-culturation of the antigen-presenting cell with the regulatory T cell, the killer cell, the helper T cell and the control cell, respectively, for an individual pig that is immunized by different PRRS antigens according to an embodiment of the present invention;
  • FIG. 4 depicts a bar diagram of a TLR mRNA relative expression level of the immune adjuvant that is screened by an in vitro immune synapse system (including porcine helper T cells and alveolar macrophages) according to an embodiment of the present invention; and
  • FIG. 5 depicts a bar diagram of the IL-2 level of the immune adjuvant that is screened by an in vitro immune synapse system according to an embodiment of the present invention.
    •  DETAILED DESCRIPTION
  • Reference will now be made in detail to the present embodiments of the invention, examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers are used in the drawings and the description to refer to the same or like parts.
  • As aforementioned, the present invention provides an immunological synapse (IS) system and the method of in vitro evaluating immune response using the same, the system being an immunological synapse system including antigen-presenting cells (APCs) derived from a same individual pig and several specific T-cell subtypes isolated from peripheral blood mononuclear cells (PBMCs), which is used to evaluate the T-cell epitope of a test sample.
  • To be specific, the immunological synapse (IS) mentioned here in the present invention refers to the one formed by APCs and the T-cell subtypes of PBMCs in vitro. The aforementioned immunological synapse (IS), which is a hypothesis proposed by researchers in recent years, is defined as a stable and collaborative interaction between two or more types of cells in the immune system, and causes consequent responses of at least one cell type of the cells. This IS system fully covers essential factors required for the in vivo immune responses of an animal, including integration information between APCs and different T-cell subtypes (such as an antigen identification system), soluble factors with guiding functions (such as cell cytokines), and the intermolecular interaction for forming specific immune responses (such as the intercellular receptor-ligand binding system).
  • APC plays a critical role in initiating and maintaining the immune response. APC identifies a pathogen recognition molecular pattern (PAMP) by the pathogen recognition receptor (PRR) of an immune system, and initiates a specific immune path through signaling transduction. When APC is activated by antigens or adjuvants, profiles of various cytokines or proinflammatory cytokines are generated through identification of PRR, so as to influence the differentiation and proliferation of various T-cell subtypes, all of which can determine that the immune response trends to what kind of the immune cell or what pattern of proinflammatory cell response.
  • The toll-like receptor (TLR) is the major family of PRRs. In recent years, researches on APC and TLR have provided a great deal of new information about the development of immune mechanisms and vaccines/adjuvants both related to a TLR agonist. The TLR agonists and the cell cytokines can change the micro-environment in which the APCs contact the T cells, thereby affecting the stability during the IS formation between the two cells. The deeper we discover the effect of the TLR agonists and cell cytokines on the IS formation between a specific antigen or infected APCs and the T cells, the more we can effectively apply the TLR agonists and cell cytokines on the immune adjuvant of animal vaccines.
  • There are kinds of TLR agonists now being attempted as the immune regulator or an active ingradient in the immune adjuvant, but a specific cell cytokine is required to involve in the micro-environment in which the APC contacts the T cells, so as to form a stable IS. However, the research on how the interaction between TLR agonist and cell cytokine affects the IS formation is rare.
  • In an embodiment, an in vitro immune synapse system of the present invention can include antigen-presenting cells and several specific T-cell subtypes isolated from PBMCs, the embodiment of which can include but be not limited to at least one cell type of regulatory T (Treg) cells, natural killer (NK) cells, and T helper (Th) cells. In other embodiments, the in vitro immune synapse system can also include an antigen-presenting cells; at least one cell type of a regulatory T cell, a killer cell and a helper T cell; and a control cell.
  • One of characteristics of the present invention is that the antigen-presenting cell, the regulatory T cell, the killer cell, the helper T cell and the control cell are primary cells derived from a same individual, thereby overcoming the immune rejection. In an embodiment, the aforementioned same individual can be, for example, a specific pathogen free (SPF) pig of any known breeds. Primary cells taken from the SPF pig can exclude interference of other antigens or antibodies. If the cells were not taken from the SPF pig, the test result of the antigen-presenting cells and the several specific T-cell subtypes isolated from peripheral blood mononuclear cells might be disturbed or even not able to obtain a result consistent with the animal experimentation.
  • The antigen-presenting cells referred in the present invention are not limited to their origin from body parts, depending on test samples. In some specific examples, the antigen-presenting cells can be alveolar macrophages (or referred to as alveolar cells); Langerhan's cells of skin; interdigitating cells (IDCs) of thymus; dendritic cells (DCs), activated B cells, macrophages and the like in the spleen and lymph nodes.
  • Preferably, the regulatory T cells referred in the present invention have preferably at least CD4+/CD25+ cell marker. The killer cells have preferably at least CD4−/CD25+ cell marker. The helper T cells have preferably at least CD4+/CD25− cell marker. There is no limitation on cell types of the control cells; however, the control cells have preferably at least CD4−/CD25− cell marker, and in an example, they can be mononuclear cells.
  • In the aforementioned in vitro immune synapse system, the number of antigen-presenting cells is preferably larger than the total number of regulatory T cells, killer cells and helper T cells. Preferably, the number of antigen-presenting cells can be 2 to 10 times of total number of regulatory T cells, killer cells and helper T cells. In other embodiments, the number of antigen-presenting cells can also be larger than total number of regulatory T cells, killer cells, helper T cells and control cells. Preferably, the number of antigen-presenting cells can be 2 to 10 times of the total number of regulatory T cells, killer cells, helper T cells and control cells.
  • The aforementioned in vitro immune synapse system can be applied to the method of in vitro evaluating immune response. In an embodiment, first of all, the aforementioned in vitro immune synapse system is provided.
  • Next, the test sample is co-cultured in the aforementioned immune synapse system for a given period. The test sample referred to in the present invention can be, for example, antigens or adjuvant, wherein types of the antigens and adjuvant should be known to one of ordinary skills in the art of the present invention rather than being recited herein.
  • The co-culturation referred in the present invention can include matching the antigen-presenting cells to any of several specific T-cell subtypes isolated from PBMCs, for example, matching the antigen-presenting cells to the regulatory T cells, the antigen-presenting cells with the helper T cells, and the antigen-presenting cells with the killer cells.
  • In the aforementioned embodiment, the aforementioned co-culturation can be implemented in a cell culture medium suitable for antigen-presenting cells and peripheral blood mononuclear cells. In general, the kinds of the cell culture medium is not limited but can be commercial products such as RPMI 1640 medium with 10% of pig serum or not.
  • In the aforementioned embodiment, a given period of the aforementioned co-culturation can be, for example, 6 to 24 hours, or 12 to 24 hours, or preferably 18 to 24 hours, and more preferably 24 hours.
  • Then, the immunization-related changes are to be evaluated after co-culturation of the aforementioned matched cells.
  • Then, the aforementioned immune synapse system is detected for any immunization-related changes. In general, the detection items for immunization-related changes are not limited, which can be, for example, a toll-like receptor (TLR) gene expression level, cytokine concentration and so on in an embodiment. The TLR gene expression level recited in the present invention can include but be not limited to the TLR3 gene expression level, TLR7 gene expression level and/or TLR8 gene expression level. The cell cytokine concentration referred in the present invention can be, for example, the interleukin (IL) concentration, including but being not limited to IL-2 concentration and/or IL-10 concentration.
  • When the immunization-related changes of any one of regulatory T cells, killer cells, helper T cells significantly differ from the immunization-related changes of control cells, it can be determined the aforementioned test sample is immunogenic or immunostimulatory. The significant difference described in the present invention refers to the statistically significant difference, typically P<0.05.
  • Taking the porcine reproductive and respiratory syndrome virus (PRRSV) as an example, the PRRSV is a major cause leading to serious respiratory symptoms of pigs in Taiwan. Once affected by PRRSV, a pig will be subjected to a high death rate, thereby extremely lowering the pig farm productivity. PRRSV mainly affects pig APCs, especially immune functions between APCs affected by viruses and regulatory T cell (Treg) cells, changes immune cell activity, induces the differentiation and hyperplasia of different T-cell subtypes, reduces the antivirus immune response of the host, and thus makes the PRRSV avoid the host immune function. In recent years, the high pathogenic (HP) PRRSV has further caused serious porcine respiratory symptoms and great economic losses to the pig farming industry. Therefore, in the respiratory mucosa immune system, it is the most important topic regarding to enhancing the mucosa immune vaccine development that the antigen-presenting cell (APC) immune activity of the respiratory mucosa immune system is activated. The respiratory mucosa immune system has alveolar macrophages as a primary first defense line of cells which are related to the interaction between a TLR agonist/cell cytokine and different T-cell antigen epitopes, but mechanisms used for their application in the animal mucosa immune IS formation and regulation are still outstanding. However, according to the verification of animal experimentation, the in vitro immune synapse system of the present invention does have results consistent with those of animal experimentation. Therefore, when developing new antigens or new adjuvant in future, the aforementioned in vitro immune synapse system is expected to replace animal experimentation.
  • The applications of the present invention are illustrated by several following embodiments, but do not intend to limit the present invention thereto. Various changes and modifications can be made by one of ordinary skills in the art of the present invention, without departing from the spirit and scope of the present invention.
    • Example 1 Establishing In Vitro Immune Synapse System 1.1 Isolation of Peripheral Blood Mononuclear Cells (PBMCs)
  • In this Example, the porcine PBMCs were isolated from a 4-week-old
  • SPF pig (of a breed multiplied between Landrace and Yorkshire) by known methods. It should be mentioned that the age and strains of the aforementioned SPF pig were merely illustrative while not limited to the aforementioned, and pigs of other ages and breeds could also be used.
  • Firstly, blood was collected from the jugular vein of the neck of the SPF pig, by a 20 mL blood collection syringe containing 1 mL of 0.5M EDTA. Then, the blood was aliquoted and centrifuged for 25 minutes, from which a buffy coat was taken and uniformly mixed with Hank's balanced salt solution (HBSS, free of calcium and magnesium ions) at a ratio of 1:2. Next, the cell mixture solution was slowly poured onto a Ficoll-Hypaque™ lymph cell separation medium and centrifuged under 4° C. at 900×g for 30 minutes. After that, the PBMC layer was collected, then rinsed for 3 times by HBSS, adjusted its cell concentration by a RPMI-1640 cell culture medium containing 10% of pig serum (abbreviation as PS-RPMI), and then placed and cultured in an incubator under 37° C. for later use.
    • 1.2 Sorting and Culturing of Pig T-Cell Subtypes
  • The aforementioned and isolated porcine PBMCs were collected the cell density of the cell solution were adjusted well, followed by adding the anti-porcine CD4 antibody and anti-porcine CD25 antibody into the cell solution, reacting the cell solution with the secondary antibodies, the cell solution was centrifuged at a 1000×g for 5 minutes. Removing the supernatant, phosphate buffered solution (PBS) was added to resuspend the cell pellet, and Coulter Epics Altra Flow Cytometry (Beckman Coulter, Calif., USA) was used to analyze cell surface marks and sort cells. After the collection of the target cells, they were centrifuged to remove the supernatant, rinsed cells for 3 times by PBS, and added with PS-RPMI culture solution so as to resuspend the cells, and then placed and cultured them in an cell incubator under 37° C. In addition, the cell solution was added with the anti-porcine CD4 and anti-porcine CD25 antibodies, and sorting quadrants were set by computer, in order to obtain the cell markers CD4+/CD25− (i.e., Th cell), CD4−/CD25+(i.e., NK cell), CD4+/CD25+ (i.e., Treg cell), and CD4−/CD25− (i.e., control cell). The aforementioned cells were centrifuged to remove the supernatant, and then rinsed for 3 times by PBS, and added into the PS-RPMI medium to resuspend the cells, placed them into a cell incubator under 37° C. for culturation.
    • 1.3 Isolation of Porcine Alveolar Macrophages
  • In this Example, a SPF pig was anesthetized and immediately its lungs were excised. 200 mL of PBS was injected into the lungs through an endotracheal tube for rinsing and gently rubbing the lungs, and then the flushing fluid was collected. The flushing fluid was collected by a 50 mL plastic centrifuge tube, and centrifuged under 4° C. at 200×g for 10 minutes, thereby collecting the cells deposited at the bottom, resuspend the cells in the PS-RPMI cell culture medium, and adjusting the cell concentration for subsequent use as antigen-presenting cells.
    • 1.4 Evaluation of In Vitro Immune Synapse System
  • In this Example, alveolar macrophages were respectively cultured in a 24-well cell culture plate with the RPMI-1640 culture medium, in which each well had 0.5 mL of antigen-presenting cell suspension (1×107 cells/mL). After cultured in an incubator containing 5% CO2 under 37° C. for 24 hours, the cells were added with different sorted T-cell subtypes (i.e. Treg cells, Th cells, NK cells and control cells), respectively. Each T-cell subtype was adjusted to 1×106 cells/mL, and 0.5 mL/well of cells for co-culture was added with antigen protein (2 μg/10 μL/well), and then added with the RPMI-1640 culture medium to a total volume of 1 mL for co-culture for 24 hours. During this evaluation, two repeats were used to identify the influence of different culture durations and antigen concentrations on the IS formation. The cells were then reacted with 4-fold volume of 2% paraformaldehyde under 4 pa for 20 minutes of incubation, then added with equal volume of ammonium chloride under the room temperature for 20 minutes of incubation, followed by centrifuged at 500×g for 10 minutes. The cell layer was collected, added with fixed buffer solution, placed on ice for 10 minutes of incubation, and then analyzed for IS formation by the election microscopy.
  • The immunological synapse was a stable junction formed by antigen-presenting cells and target T cells, and also played a key role in the activation of the immune system. The interaction between macrophages and T cells and the synapse structure formed by the two cells could be observed by transmission electron microscopy (TEM) and scanning election microscopy (SEM).
  • Referring to FIGS. 1A to 1D, which were depicted TEM images (FIGS. 1A to 1C) and SEM image (FIG. 1D) of a porcine alveolar macrophage 101 matching to a regulatory T cell 103 (FIGS. 1A and 1B) or matching to a helper T cell 105 (FIGS. 1C and 1D) according to an embodiment of the present invention.
  • As shown in the results of FIGS. 1A to 1D, during the first stage of the co-culture, the regulatory T cell 103 would extend pseudopodia toward the alveolar macrophage 101 (as shown in FIG. 1A). During the second stage, the alveolar macrophage 101 and the regulatory T cell 103 showed centriole proximity (as shown in FIG. 1B). During the third stage, the Golgi complex of the alveolar macrophage 101 enlarged, the interface between the two cells was flatten (as shown in FIG. 1C) and formed to the immunological synapse (as shown in FIG. 1D), proving that the two cells were able to form the immune synapse system in vitro.
    • Example 2 Verification of Immune Synapse System by Animal Experimentation
  • Twelve 4-week-old SPF pigs were divided into 3 groups (4 per group), including respectively a negative control group, a “antigen 1” group without T-cell epitope (free of T-cell antigen epitope; PRRSV-1), and an “antigen 2” group (containing T-cell antigen epitope; PRRSV-2), respectively, all groups being subjected to pig immunization plan which included the first immunization on the pigs of 4 weeks old and the second immunization on the pigs of 6 weeks old. The “antigen 1” did not contain specific T-cell antigen epitope additionally, and the “antigen 2” contained specially T-cell antigen epitope additionally that was designed by inventors, wherein the T-cell antigen epitope of PRRSV as “antigen 2” had a sequence designed by the inventors. However, PRRSV-1 and PRRSV-2 were merely illustrative examples for verifying the immune synapse system, and other known sequences could also be used without repeatedly described herein.
  • The aforementioned SPF pigs were sacrificed at 8 weeks old, and the alveolar macrophages and PBMCs were isolated respectively, in which the alveolar macrophages were used as the antigen-presenting cell (APC) which was then co-cultured with specific T-cell subtypes (i.e., Th cell, NK cell, Treg cell and control cell) sorted from the blood PBMCs by a flow cytometry, for providing evaluation on its function influenced by the animal immunization. The TLR gene expression and cell cytokine of the in vitro immunological synapse were analyzed for verification of the in vitro immunological synapse as screening platforms in later use.
    • 2.1 Evaluation of Changes in TLR Gene Expression
  • The TLR gene expression level of the aforementioned specific T-cell subtypes upon immunostimulation was measured by the following or conventional methods. Firstly, total RNA of the aforementioned specific T-cell subtypes was extracted by Trizol® reagent and Direct-Zol® column. After quantification by a spectrophotometer, a commercial kit [such as PrimeScript™ RT reagent kit (Takara)] was used for synthesizing cDNA according to operation steps of the kit. Briefly, 0.5 μg of RNA was added into 2 μL of 5× PCR buffer solution, 0.5 μL of PrimeScript™ RT enzyme mix I, 0.5 μL of oligo-dT primer (50 μM), 0.5 μL of random primer (100 μM). The volume of each reaction was added to 10 μL by double distilled (dd) H2O, and it was then treated under 42° C. for 30 minutes. The expression level of TLR gene could be determined by the following primers and real time PCR.
  • The upstream primer of TLR3 gene was a sequence listed as SEQ ID NO: 1, while the downstream primer of TLR3 gene was a sequence listed as SEQ ID NO: 2. The upstream primer of TLR7 gene was a sequence listed as SEQ ID NO: 3, while TLR7 gene downstream primer was a sequence listed as SEQ ID NO: 4. The upstream primer of TLR8 gene was a sequence listed as SEQ ID NO: 5, while the downstream primer of TLR8 gene was a sequence listed as SEQ ID NO: 6.
  • Referring to FIGS. 2A to 2C, which were bar diagrams of mRNA relative expression levels of toll-like receptors (TLRs) 3 (FIG. 2A), TLR 7 (FIG. 2B), and TLR 8 (FIG. 2C) upon the in vitro co-culturation of an antigen-presenting cell with a regulatory T cell, a killer cell, a helper T cell and a control cell, respectively, for an individual pig immunized by various PRRS antigens according to an embodiment of the present invention. mRNA relative expression levels of TLR 3, TLR 7, and TLR 8 in FIGS. 2A to 2C were represented by −ΔΔCt in the geometric mean (2−ΔΔCt. The statistical significance between two groups (P<0.05) was represented by their bars labeled by different letters of FIGS. 2A to 2C.
  • As shown by the results in FIGS. 2A to 2C, for the pigs immunized with PRRSV-1 and PRRSV-2, the immunological synapse functional expressions of antigen-presenting cells and different T-cell subtypes have been indeed effectively improved, TLR 3, TLR 7, and TLR 8 gene expressions related to virus presenting capability have been improved as well, and the differences between these values had statistical significances.
    • 2.2 Evaluation of Change of Cell Cytokine Level
  • In this Example, a commercial kit of porcine IL-2 and IL-10 was used for quantifying the IL-2 and IL-10 levels in the porcine cell supernatant. According to the steps of the specification provided in the kit, the standard liquid provided by the kit was diluted for later use, and a flow was described briefly below. Firstly, 100 μL of sample or diluted standard liquid was added into a 96-well plate and incubated for 1 hour. Next, 200 μL of biotinylated antibody reagent was added into the 96-well plate and incubated for another hour. Then, 100 μL of streptavidin-HRP labeled by horseradish peroxidase (HRP) was added therein and incubated for 30 minutes, followed by adding 100 μL of 3,3′,5,5′-tetramethylbenzidine (TMB) substrate solution for dark incubation of 30 minutes. Afterwards, 100 μL of stop solution was added to terminate the reaction in order to measure the absorbance. Each well was washed 3 to 5 times with the wash buffer after each incubation step. All steps were performed under the room temperature.
  • Generally, the absorbance could be read by a commercial continuous spectrophotometer at a wavelength of 450/540 nm, and a standard curve was established by serially-diluted standard solution of various concentrations versus respective absorbances. Then, the cell cytokine concentration of each sample was calculated according to the regression equation of the standard curve, and a commercially statistical software (such as a SAS statistical program) was used to calculate significant difference between the means of all groups, as shown by the results of FIGS. 3A to 3B.
  • Referring to FIGS. 3A to 3B, which depicted bar diagrams of the IL-2 (FIG. 3A) level and IL-10 (FIG. 3B) level upon the co-culturation of an antigen-presenting cell with a regulatory T cell, a killer cell, a helper T cell and a control cell, respectively, for an individual pig that was immunized by PRRS antigens according to an embodiment of the present invention. The statistical significance between two groups (P<0.05) was represented by their bars labeled by different letters of FIGS. 3A to 3B.
  • As shown by the results of FIGS. 3A to 3B, after the pigs were immunized with PRRSV-1 and PRRSV-2, the IL-2 (having immunoenhancement) level could be effectively increased while the IL-10 (having immunosuppression) level was reduced. Especially when those pigs were immunized by PRRSV-2 containing the T-cell antigen epitope, the IL-10 level was inhibited more significantly, and the differences between these values had statistical significances.
    • Example 3 Application of In Vitro Immune Synapse System 3.1 Evaluation of Immunogenicity of Antigen
  • Firstly, using the same method as Example 1, alveolar macrophages and sorted T-cell subtypes were isolated from six 4-week-old specific pathogen free (SPF) pigs and co-cultured in a 24-well plate in order to establish an in vitro immune synapse system.
  • Next, the aforementioned in vitro immune synapse system was added with the antigen protein (the treatment group, 2 μg of PRRSV-1 or PRRSV-2) or without the antigen protein (the control group), and then the system was co-cultured in a CO2 incubator under 37° C. for 24 hours. After the culturation, the 24-well plate was centrifuged at 300×g for 15 minutes, and supernatants were respectively collected for detecting cell cytokines. Meanwhile, a Trizol® reagent (ThermoFisher Scientific) was used to dissolve the cell pellet, and the TLR gene expression was detected in the same method as Example 2, as shown by the result of FIG. 4.
  • Referring to FIG. 4, which showed a bar diagram of a TLR mRNA relative expression level when the immune adjuvant was screened by an in vitro immune synapse system (including porcine helper T cells and alveolar macrophages) according to an embodiment of the present invention. The statistical significance between two groups (P<0.05) was represented by their bars labeled by different letters of FIG. 4.
  • As shown by the result in FIG. 4, the PRRS antigen (i.e., PRRSV-1 or PRRSV-2) did significantly improve the gene expression levels of TLR 3, TLR 7, and TLR 8 of the immunological synapse, and the differences between these values had statistical significances.
    • 3.2 Evaluation of Immunostimulation of Immune Adjuvant
  • In addition, after the in vitro immune synapse system (NK/APC or Treg/APC) of Example 1 was co-cultured with an immune adjuvant or not (control group), the IL-2 level was detected by the same method as Example 2. The aforementioned immune adjuvant was poly IC (Sigma-Aldrich) and IL-18 (Sigma-Aldrich Co.). 2 μL of Poly IC (1 mg/mL) (Sigma-Aldrich Co.) was added into the cell sap per well (2 μg/well), or 100 μL IL-18 (1 ng/mL) (Sigma-Aldrich) was added into the cell sap per well (0.1 ng/well). The detection methods for poly IC and IL-18 are referenced from J. Immunol. 162 (10):6114-6121 (May 15, 1999) and J. Immunol. 176:1348-1354 (2006), which are both incorporated by reference into the present invention.
  • Referring to FIG. 5, which depicted a bar diagram of the IL-2 level (μg/mL) of the immune adjuvant that was screened by an in vitro immune synapse system according to an embodiment of the present invention. The statistical significance between two groups (P<0.05) was represented by their bars labeled by different letters of FIG. 5.
  • As shown by the result in FIG. 5, the in vitro immune synapse system in which Treg cells matched to APC cells could form the immunological synapse. In comparison to IL-18, the poly-IC could significantly improve the IL-2 level in the immunological synapse, and the differences between these values had statistical significances.
  • In general, although the present invention utilizes cells from a specific source for establishing the in vitro immune synapse system, specific analysis methods or specific evaluations as examples to illustrate the in vitro immune synapse system of the present invention and the method of in vitro evaluating immune response using the same, any one of ordinary skills in the art of the present invention can realize that the present invention is not limited thereto. Without departing from the spirit and scope of the present invention, cells from other sources can also be used for establishing the in vitro immune synapse system of the present invention and other analyzing methods or other evaluations can also be carried out in the method of in vitro evaluating immune response using the same.
  • It can be seen from the aforementioned embodiments that an in vitro immune synapse system of the present invention and the method of in vitro evaluating immune response using the same are advantageous in the in vitro immune synapse system containing antigen-presenting cells derived from a same individual pig and several specific T-cell subtypes isolated from peripheral blood mononuclear cells, so as to evaluate the T-cell antigen epitope of a test sample. Through the verification of animal experimentation, the aforementioned in vitro immune synapse system indeed has results consistent with those of animal experimentation. Therefore, when developing new antigens or new adjuvants in the future, the aforementioned in vitro immune synapse system is expected to replace animal experimentation.
  • Although the present invention has been described in considerable detail with reference to certain embodiments thereof, other embodiments are possible. Therefore, the spirit and scope of the appended claims should not be limited to the description of the embodiments contained herein.
  • It will be apparent to those skilled in the art that various modifications and variations can be made to the structure of the present invention without departing from the scope or spirit of the invention. In view of the foregoing, it is intended that the present invention cover modifications and variations of this invention provided they fall within the scope of the following claims.

Claims (12)

What is claimed is:
1. An in vitro immune synapse system, comprising:
an antigen-presenting cell; and
at least one cell type of a regulatory T cell, a killer cell and a helper T cell, and
wherein the antigen-presenting cell, the regulatory T cell, the killer cell and the helper T cell are primary cells derived from a same individual, and a number of the antigen-presenting cell is larger than a total number of the regulatory T cell, the killer cell and the helper T cell.
2. The in vitro immune synapse system of claim 1, wherein the same individual is a specific pathogen free (SPF) pig.
3. The in vitro immune synapse system of claim 1, wherein the antigen-presenting cell is an alveolar macrophage.
4. The in vitro immune synapse system of claim 1, wherein the number of the antigen-presenting cell is 2 to 10 times of the total number of the regulatory T cell, the killer cell and the helper T cell.
5. The in vitro immune synapse system of claim 1, further comprising a control cell, wherein the control cell is derived from the same individual, and the control cell has at least a CD4−/CD25− cell marker.
6. The in vitro immune synapse system of claim 5, wherein the control cell is a mononuclear cell.
7. A method of in vitro evaluating immune response, comprising:
providing an in vitro immune synapse system, wherein the in vitro immune synapse system comprises:
an antigen-presenting cell;
at least one of a regulatory T cell, a killer cell and a helper T cell; and
a control cell, and
wherein the antigen-presenting cell, the regulatory T cell, the killer cell, the helper T cell and the control cell are primary cell derived from a same individual, and a number of the antigen-presenting cell is 2 to 10 times of a total number of the regulatory T cell, the killer cell and the helper T cell;
co-culturing a test sample in the immune synapse system for 24 hours; and
detecting the immune synapse system for an immunization-related change, wherein the immunization-related change comprises an level of toll-like receptor (TLR) gene expression and/or a cytokine concentration, and
wherein when any one of the regulatory T cell, the killer cell, the helper T cell has its immunization-related change significantly differ from the immunization-related change of the control cell, the test sample is determined to be immunogenic or immunostimulatory.
8. The method of in vitro evaluating immune response of claim 7, wherein the test sample comprises an antigen or an adjuvant.
9. The method of in vitro evaluating immune response of claim 7, wherein the same individual is a SPF pig.
10. The method of in vitro evaluating immune response of claim 7, wherein the antigen-presenting cell is an alveolar macrophage, the regulatory T cell has at least a CD4+/CD25+ cell marker, the killer cell has at least a CD4−/CD25+ cell marker, the helper T cell has at least a CD4+/CD25− cell marker, the control cell is a mononuclear cell, and the control cell has at least a CD4−/CD25− cell marker.
11. The method of in vitro evaluating immune response of claim 7, wherein the TLR gene expression level comprises the TLR3 gene expression level, the TLR7 gene expression level, and/or the TLR8 gene expression level.
12. The method of in vitro evaluating immune response of claim 7, wherein the cell cytokine concentration comprises an interleukin (IL) concentration.
US16/219,006 2018-12-13 2018-12-13 In vitro immune synapse system and method of in vitro evaluating immune response using the same Abandoned US20200190471A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/219,006 US20200190471A1 (en) 2018-12-13 2018-12-13 In vitro immune synapse system and method of in vitro evaluating immune response using the same
US17/021,158 US11834647B2 (en) 2018-12-13 2020-09-15 In vitro immune synapse system and method of in vitro evaluating immune response using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16/219,006 US20200190471A1 (en) 2018-12-13 2018-12-13 In vitro immune synapse system and method of in vitro evaluating immune response using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/021,158 Division US11834647B2 (en) 2018-12-13 2020-09-15 In vitro immune synapse system and method of in vitro evaluating immune response using the same

Publications (1)

Publication Number Publication Date
US20200190471A1 true US20200190471A1 (en) 2020-06-18

Family

ID=71073392

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/219,006 Abandoned US20200190471A1 (en) 2018-12-13 2018-12-13 In vitro immune synapse system and method of in vitro evaluating immune response using the same
US17/021,158 Active 2040-02-07 US11834647B2 (en) 2018-12-13 2020-09-15 In vitro immune synapse system and method of in vitro evaluating immune response using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/021,158 Active 2040-02-07 US11834647B2 (en) 2018-12-13 2020-09-15 In vitro immune synapse system and method of in vitro evaluating immune response using the same

Country Status (1)

Country Link
US (2) US20200190471A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114686431A (en) * 2022-03-30 2022-07-01 益诺思生物技术南通有限公司 Method and model for evaluating immunotoxicity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855074B2 (en) * 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
TWI615401B (en) 2013-02-23 2018-02-21 國立屏東科技大學 Soluble recombinant flic fusion protein in improving activities of porcine immune cells and prokaryotic transformant for over-expressing the same
WO2017023770A1 (en) 2015-07-31 2017-02-09 Dongfang Liu Quality of immunological synapse predicts effectiveness of chimeric antigen receptor (car) t cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114686431A (en) * 2022-03-30 2022-07-01 益诺思生物技术南通有限公司 Method and model for evaluating immunotoxicity

Also Published As

Publication number Publication date
US20200407683A1 (en) 2020-12-31
US11834647B2 (en) 2023-12-05

Similar Documents

Publication Publication Date Title
US10870885B2 (en) Dendritic cell response gene expression, compositions of matters and methods of use thereof
Geboes et al. Proinflammatory role of the Th17 cytokine interleukin‐22 in collagen‐induced arthritis in C57BL/6 mice
Behnke et al. Toxoplasma gondii merozoite gene expression analysis with comparison to the life cycle discloses a unique expression state during enteric development
Götz et al. Atypical activation of dendritic cells by Plasmodium falciparum
Vargas-Inchaustegui et al. Distinct roles for MyD88 and Toll-like receptor 2 during Leishmania braziliensis infection in mice
Månsson Kvarnhammar et al. Innate immune receptors in human airway smooth muscle cells: activation by TLR1/2, TLR3, TLR4, TLR7 and NOD1 agonists
Calzada-Nova et al. Characterization of the cytokine and maturation responses of pure populations of porcine plasmacytoid dendritic cells to porcine viruses and toll-like receptor agonists
Zacca et al. Aging impairs the ability of conventional dendritic cells to cross-prime CD8+ T cells upon stimulation with a TLR7 ligand
Wei‐guo et al. PPAR‐γ agonist inhibits Ang II‐induced activation of dendritic cells via the MAPK and NF‐κB pathways
Johnson et al. B cell presentation of Chlamydia antigen selects out protective CD4γ13 T cells: implications for genital tract tissue-resident memory lymphocyte clusters
Wang et al. Single‐cell transcriptomic atlas reveals distinct immunological responses between COVID‐19 vaccine and natural SARS‐CoV‐2 infection
Jans et al. Siglec‐1 inhibits RSV‐induced interferon gamma production by adult T cells in contrast to newborn T cells
US11834647B2 (en) In vitro immune synapse system and method of in vitro evaluating immune response using the same
Boccasavia et al. Antigen presentation between T cells drives Th17 polarization under conditions of limiting antigen
Fontana et al. Nuclear receptor ligands induce TREM-1 expression on dendritic cells: analysis of their role in tumors
Stephens et al. Epithelial-myeloid exchange of MHC class II constrains immunity and microbiota composition
Van Hemert et al. Immunological and gene expression responses to a Salmonella infection in the chicken intestine
He et al. Rapid loss of CD4 T cells by pyroptosis during acute SIV infection in rhesus macaques
Kerepesi et al. Protective immunity to the larval stages of Onchocerca volvulus is dependent on Toll-like receptor 4
Schmitt et al. A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice
Witczak et al. The response of tissue mast cells to TLR3 ligand poly (I: C) treatment
Humphreys et al. Dysregulated immune profiles for skin and dendritic cells are associated with increased host susceptibility to Haemophilus ducreyi infection in human volunteers
Tallmadge et al. Transcriptome analysis of immune genes in peripheral blood mononuclear cells of young foals and adult horses
Mandraju et al. MyD88 signaling in T cells is critical for effector CD4 T cell differentiation following a transitional T follicular helper cell stage
TWI770327B (en) In vitro immune synapse system and method of in vitro evaluating immune response using the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY, TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHAUNG, HSO-CHI;CHUNG, WEN-BIN;CHEN, ANN YING-AN;AND OTHERS;REEL/FRAME:047767/0232

Effective date: 20181207

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION